Biological Response Modifiers, Leukaemias and Lymphomas |
Contents
P A Bunn Jr D C Ihde and K A Foon | 1 |
R Ohno and K Kimura | 15 |
G R C McLeod D B Thomson and P Hersey | 23 |
Copyright | |
6 other sections not shown
Other editions - View all
Common terms and phrases
acute alfa-IFNs antibodies antigens Ara-C assay ATK activity augmentation auto-tumor autologous tumor cells Basel/Akadémiai Kiadó Biological Response Modifiers blood lymphocytes bone marrow Budapest Cancer Congr carcinoma chemotherapy clinical studies combination complete remission complete response CR rate cytokines cytotoxic cytotoxic factors daunorubicin dose doxorubicin doxorubicin-DNA drug effect of OK-432 effector cells enhanced evaluation Hoshino IFN-alfa-2a Immunol immunotherapy injection interferon alfa-2a irradiation KE/animal Lapis/Eckhardt eds Lectures and Symposia Leukaemias and Lymphomas leukemia LGL-CF and MO-CF lung lymph nodes lymphocytes Lymphomas Lectures lyse lysis malignant median melanoma metastases mg/m˛ mice MICKSCHE monocytes months multiple myeloma natural killer NK activity NK cells NKCF oral peripheral blood Phase I-A Picibanil pleural effusion protocol recombinant interferon alfa-2a reduction remission duration remission induction response rate Roferon-A stimulation streptococcal preparation supernatant surgery survival Symposia 14th Int Table tested therapeutic toxicity treated treatment Uchida vitro